Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT05656105
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • SARS CoV-2 Post-Acute Sequelae

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • DPA-714 PET/MRI — DRUG
    DPA-714 PET/MRI

Study Details

This clinical imaging study will use the small molecule translocator protein (TSPO) ligand, Fluorodeoxyglucose(18F)-labeled DPA-714, to visualize and quantify neuroinflammation in individuals with post-acute sequelae of SARS-CoV-2 (PASC) . The brain uptake of DPA-714 will be contrasted with healthy subjects.

Key Dates

Start date
Nov 10, 2023
Status verified
Dec 2025
Primary completion
Jun 1, 2028
Completion
Jun 1, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Healty Volunteers
  • Experimental: PASC
    Patients meeting the case definition criteria for PASC

Primary Outcome Measure

Measurement of regional brain TSPO levels using PET in participants with neurological PASC and healthy volunteers [ Time Frame: Injection/scan date to clinical follow-up. (Usually within 6 weeks) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UABBirminghamAlabama35249
April Riddle
[email protected]
2059961082
Jonathan McConathy, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By research site
UAB· Birmingham, AL